HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown and numerous pharma lawsuits, nearly 1 in 5 patients are taking cheaper weight-loss alternatives despite the risks.

By PharmaVoice · Jul 17, 2026 · via PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansion…
Jul 19, 2026
The WeekFierceBiotech ↗
Jasper Therapeutics is being reborn via a merger with Nasdaq-listed immune-mediated disease biotech Kira Pharm…
Jul 19, 2026
Veradermics' Hair-Loss Pill Shows Strong Phase 2 Signal in Women
The WeekBriefing
Veradermics' oral minoxidil exceeded expectations in Phase 2, sending shares near $130 and strengthening its c…
Jul 19, 2026